PEAK6’s Dianthus Therapeutics DNTH Stock Holding History

PEAK6’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,925	Closed	-$245K	–	2843
2026 Q1	$245K	Buy	+2,925	New	+$169K	﹤0.01%	2219

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

PEAK6's DNTH Position: Q2 2026 in Review

PEAK6 sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 2,925 shares — an estimated $245K sold.

PEAK6 first reported a position in DNTH in Q1 2026 and held it in 1 quarter. The position peaked at $245K in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

PEAK6 reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
PEAK6 sold 2,925 Dianthus Therapeutics shares in Q2 2026, an estimated $245K.
PEAK6 first reported a position in Dianthus Therapeutics in Q1 2026 and held it in 1 quarter.
PEAK6's Dianthus Therapeutics position peaked at $245K in Q1 2026.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.